Sanofi is conducting a Phase 3 clinical trial titled A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing ...

Results of a meta-analysis showed that a history of allergies, multiorgan involvement, and decreased complement levels were linked to higher risk for IgG4-RD relapse.

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the ...

Prostate involvement was first reported in IgG4-RD approximately 2 decades ago and comprises only 9.6% of cases. A male patient in his 7os presented with isolated prostatitis associated with ...

Zenas BioPharma secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology ...